Physician profile
Garth Grey
NPI 1306428792
$1,839.33
in general payments reported to CMS, 2019-2025
18 companies · $669 in 2025
The $669 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $482 · 2024: $687 · 2025: $669.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,839.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,839.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $286.08 | 2024-2025 | Airsupra, Breztri |
| Novo Nordisk INC | $237.66 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $206.53 | 2023-2025 | |
| Abbvie INC. | $201.36 | 2023-2025 | |
| Lilly USA, LLC | $144.76 | 2023-2025 | Mounjaro, Zepbound, Reyvow |
| Glaxosmithkline, LLC. | $125.26 | 2023-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Amgen INC. | $109.97 | 2024-2025 | Evenity, Prolia, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $103.10 | 2024-2025 | Xifaxan |
| Astellas Pharma US INC | $98.36 | 2024-2025 | Veozah |
| Exact Sciences Corporation | $85.70 | 2023-2024 | Cologuard Collection Kit |
| Radius Health, INC. | $65.84 | 2024-2025 | Tymlos |
| Dexcom, INC. | $40.93 | 2025 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $27.04 | 2023 | Pneumovax 23, Vaxneuvance, Gardasil 9 |
| Janssen Pharmaceuticals, INC | $26.36 | 2023 | Xarelto |
| Idorsia Pharmaceuticals US INC | $23.28 | 2023 | Quviviq |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.36 | 2024 | Jardiance |
| Bausch Health US, LLC | $21.79 | 2025 | Aplenzin |
| Currax Pharmaceuticals LLC | $12.95 | 2023 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Garth Grey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.